Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2009 Aug;124(2):286-91, 291.e1-6.
doi: 10.1016/j.jaci.2009.03.045. Epub 2009 May 27.

Safety of a peanut oral immunotherapy protocol in children with peanut allergy

Alison M Hofmann  1 , Amy M Scurlock, Stacie M Jones, Kricia P Palmer, Yuliya Lokhnygina, Pamela H Steele, Janet Kamilaris, A Wesley Burks
Affiliations
Clinical Trial

Safety of a peanut oral immunotherapy protocol in children with peanut allergy

Alison M Hofmann et al. J Allergy Clin Immunol. 2009 Aug.

Abstract

Background: Oral immunotherapy (OIT) offers a promising therapeutic option for peanut allergy. Given that during OIT an allergic patient ingests an allergen that could potentially cause a serious reaction, the safety of OIT is of particular concern.

Objective: The purpose of this study was to examine safety during the initial escalation day, buildup phase, and home dosing phase in subjects enrolled in a peanut OIT study.

Methods: Skin, upper respiratory tract, chest, and abdominal symptoms were recorded with initial escalation day and buildup phase dosings. Subjects also maintained daily diaries detailing symptoms after each home dosing. A statistical analysis of these data was performed.

Results: Twenty of 28 patients completed all phases of the study. During the initial escalation day, upper respiratory tract (79%) and abdominal (68%) symptoms were the most likely symptoms experienced. The risk of mild wheezing during the initial escalation day was 18%. The probability of having any symptoms after a buildup phase dose was 46%, with a risk of 29% for upper respiratory tract symptoms and 24% for skin symptoms. The risk of reaction with any home dose was 3.5%. Upper respiratory tract (1.2%) and skin (1.1%) symptoms were the most likely after home doses. Treatment was given with 0.7% of home doses. Two subjects received epinephrine after 1 home dose each.

Conclusions: Subjects were more likely to have significant allergic symptoms during the initial escalation day when they were in a closely monitored setting than during other phases of the study. Allergic reactions with home doses were rare.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Estimated Risk of Specific Symptoms during the Initial Escalation Day. Symptoms were recorded during the initial escalation day in four categories: upper respiratory, skin, abdominal, and chest.
Figure 2
Figure 2
Estimated Risk of Specific Symptoms During the Build-up Phase. Symptoms were recorded during the buildup phase in four categories: upper respiratory, skin, abdominal, and chest.
Figure 3
Figure 3
Estimated Risk of Specific Symptoms During the Home Dosing Phase. Symptoms were recorded during the home dosing phase in four categories: upper respiratory, skin, abdominal, and chest.
See this image and copyright information in PMC

References

    1. Sicherer S, Munoz-Furlong A, Sampson HA. Prevalence of peanut and tree nut allergy in the United States determined by means of a random digit dial telephone survey: A 5-year follow-up study. J Allergy Clin Immunol. 2003;112(6):1203–1207. - PubMed
    1. Sicherer SH, Burks AW, Sampson HA. Clinical Features of Acute Allergic Reactions to Peanut and Tree Nuts in Children. Pediatrics. 1998;102(1):e6. - PubMed
    1. Fleischer DM. The natural history of peanut and tree nut allergy. Curre Allergy Asthma Rep. 2007;7(3):175–81. - PubMed
    1. Fleischer DM, Conover-Walker MK, Christie L, Burks AW, Wood RA. Peanut allergy: Recurrence and its management. J Allergy Clin Immunol. 2004;114(5):1195–201. - PubMed
    1. Nelson HS, Lahr J, Rule R, Bock A, Leung D. Treatment of analphylactic sensitivity to peanuts by immunotherapy with injections of aqueous peanut extract. J Allergy Clin Immunol. 1997;99(6 Pt1):744–751. - PubMed

Publication types